<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083197</url>
  </required_header>
  <id_info>
    <org_study_id>START</org_study_id>
    <nct_id>NCT03083197</nct_id>
  </id_info>
  <brief_title>Scrub Typhus Antibiotic Resistance Trial</brief_title>
  <acronym>START</acronym>
  <official_title>The Scrub Typhus Antibiotic Resistance Trial (START) Comparing Doxycycline and Azithromycin Treatment Modalities in Areas of Reported Antimicrobial Resistance for Scrub Typhus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shoklo Malaria Research Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chiangrai Prachanukroh Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study type: Randomized Control Treatment Trial&#xD;
&#xD;
      Study population: Male and female patients with ≥15 years of age and acute scrub typhus&#xD;
&#xD;
      Duration: 2 years&#xD;
&#xD;
      Study Design: Prospective, open-label, randomized-controlled treatment trial in patients ≥15&#xD;
      years old admitted to hospital with acute scrub typhus. Randomization into 3 oral treatment&#xD;
      arms (each n=59 patients, total n=177): i) 7 days of doxycycline, ii) 3 days of doxycycline,&#xD;
      and iii) 3 days of azithromycin&#xD;
&#xD;
      Primary Objective: To evaluate the clinical and microbiological responses in scrub typhus&#xD;
      patients to three oral treatment regimens: 7 days of doxycycline, 3 days of doxycycline, and&#xD;
      3 days of azithromycin&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To perform pharmacokinetic/pharmacodynamics (PK/PD) characterization of the therapeutic&#xD;
           responses for doxycycline and azithromycin, incl. serial bacterial load measurements.&#xD;
&#xD;
        2. To define clinical, bacterial, pathophysiological and pharmacological factors associated&#xD;
           with disease severity, fever-clearance times (FCT), treatment failures and&#xD;
           relapse/re-infection.&#xD;
&#xD;
        3. To determine the minimum inhibitory concentrations (MIC) of clinical Orientia&#xD;
           tsutsugamushi isolates to doxycycline, azithromycin and chloramphenicol, using in vitro&#xD;
           growth-inhibition assays&#xD;
&#xD;
        4. To genotype all clinical isolates using whole genome sequencing for comparative&#xD;
           genomics.&#xD;
&#xD;
        5. To dissect the natural immune response in scrub typhus, using antigen-specific cellular&#xD;
           immune and antibody studies, and cytokine profiling&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The funder is USAMRMC - MIDRP and Grant No. DHP-Award D6.7_15_C2_I_15_J9_1317&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2017</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fever clearance time (FCT)</measure>
    <time_frame>at least 24 hours</time_frame>
    <description>Based on the time from first dose of antibiotic treatment to when the tympanic temperature first falls ≤37.5°C and remains ≤37.5°C for at least 24 hours, outside of the influence of paracetamol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of bacteraemia in relation to Drug plasma level</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of severe disease or treatment failure/relapse</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of in vitro antimicrobial resistance</measure>
    <time_frame>8 Weeks</time_frame>
    <description>(Minimum inhibitory concentrations (MIC) over susceptibility cut off)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping of clinical Orientia tsutsugamushi isolates (56kDa gene +/- whole genome sequencing)</measure>
    <time_frame>2 years</time_frame>
    <description>Genotyping of clinical OT isolates will be performed on patient samples that are PCR positive (approximately 50-60%) and/or culture positive (approximately 30%). Extracted DNA will be sent for 56kDa gene sequencing +/- whole genome sequencing, revealing the clinically important strains and allowing for comparative analysis with disease severity and patient outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antigen-specific positive cellular and humoral immune responses</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Scrub Typhus</condition>
  <arm_group>
    <arm_group_label>Doxycycline 7 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>loading dose 200mg PO, then 100mg PO every 12 hours for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>loading dose 200mg PO, then 100mg PO every 12 hours for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin 3 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 7 days</intervention_name>
    <description>loading dose 200mg PO, then 100mg PO every 12 hours for 7 days</description>
    <arm_group_label>Doxycycline 7 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 3 days</intervention_name>
    <description>loading dose 200mg PO, then 100mg PO every 12 hours for 3 days</description>
    <arm_group_label>Doxycycline 3 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 3 days</intervention_name>
    <description>loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3</description>
    <arm_group_label>Azithromycin 3 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 15 years old&#xD;
&#xD;
          -  Hospitalization with acute undifferentiated fever (temperature &gt; 37.5°C, tympanic) ≤14&#xD;
             days or patients admitted to hospital with a history of fever ≤ 14 days who&#xD;
             subsequently develop fever within 24 hours of admission&#xD;
&#xD;
          -  Clinically suspected scrub typhus: defined as acute undifferentiated fever with no&#xD;
             clear focus of infection and negative malaria blood smear and/or negative malaria RDT.&#xD;
             Patients may have one, none, or a combination of other clinical findings such as&#xD;
             eschar, rash, lymphadenopathy, headache, myalgia, cough, nausea and abdominal&#xD;
             discomfort.&#xD;
&#xD;
          -  A positive scrub typhus RDT (Scrub Typhus IgM RDT, InBios International, Seattle, WA,&#xD;
             USA) and/or positive PCR-based detection of O. tsutsugamushi DNA from the admission&#xD;
             blood sample&#xD;
&#xD;
          -  Written informed consent and/or, written informed assent as required&#xD;
&#xD;
          -  Able to take oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to tetracycline, doxycycline or azithromycin&#xD;
&#xD;
          -  Administration of doxycycline, azithromycin, chloramphenicol, rifampicin, or&#xD;
             tetracycline during the preceding 7 days&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Patients with myasthenia gravis or systemic lupus erythematosus&#xD;
&#xD;
          -  Patients with an established infection (diagnostic test required) e.g. acute malaria,&#xD;
             dengue, leptospirosis, typhoid, Japanese encephalitis etc.&#xD;
&#xD;
          -  Current TB or TB treatment in ≤ 6 months (contain active antibiotics against Orientia&#xD;
             spp.)&#xD;
&#xD;
          -  Current HAART use for HIV, long term use of immunosuppressants (e.g. steroids,&#xD;
             chemotherapy, TNF-inhibitors and related agents)&#xD;
&#xD;
          -  Patients with severe disease whom the clinical team feel their condition necessitates&#xD;
             the need for additional scrub typhus treatment beyond the allocated antibiotic&#xD;
             treatment assigned at randomization (e.g. IV chloramphenicol and/or PO/NG rifampicin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Assoc. Prof. Daniel Paris</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Assoc. Prof. Daniel Paris</last_name>
    <phone>+6622036373</phone>
    <email>parigi@tropmedres.ac</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tri Wangrangsimakul</last_name>
    <phone>+6622036333</phone>
    <email>tri@tropmedres.ac</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shoklo-Malaria Research Unit (SMRU)</name>
      <address>
        <city>Mae Sot</city>
        <state>Tak</state>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rose McGready, Prof</last_name>
      <email>rose@shoklo-unit.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tri Wangrangsimakul, MD</last_name>
      <email>Tri@tropmedres.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>September 1, 2020</last_update_submitted>
  <last_update_submitted_qc>September 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scrub Typhus</keyword>
  <keyword>Antibiotic Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhus, Epidemic Louse-Borne</mesh_term>
    <mesh_term>Scrub Typhus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

